Clinical characteristics and long-term prognosis of talaromycosis in children with novel and reported inborn errors of immunity - Takeaways - MDSpire

Clinical characteristics and long-term prognosis of talaromycosis in children with novel and reported inborn errors of immunity

  • By

  • Qian Lu

  • Xianghui Li

  • Zhiwen Jiang

  • Tiantian Li

  • Bingkun Li

  • Lan Huang

  • Qihua Huang

  • Dongmei Hu

  • Chunying Lv

  • Guoqun Liu

  • Jialing Zhong

  • Jingjing Lin

  • Liuwei Liao

  • Qianfeng Qin

  • Sha Qin

  • Haotian Shao

  • Zhiyi Wang

  • Xiuying Li

  • Li Jiang

  • Xinyu Zhang

  • Lili Wei

  • Jiarong Liang

  • Dongyan Zheng

  • Shuangjie Wang

  • Weixuan Wu

  • Kaisu Pan

  • Yanqing Zheng

  • Yanning Li

  • Qing Tang

  • Min Jiang

  • Wanqing Liao

  • Cunwei Cao

  • May 13, 2026

  • 0 min

Share

  • 1

    The study analyzed 18 pediatric patients with talaromycosis and inborn errors of immunity over a 13-year period.

  • 2

    All children diagnosed with talaromycosis had inborn errors of immunity, including both novel and known genetic anomalies.

  • 3

    Half of the children experienced severe complications, necessitating advanced life support, with a median antifungal therapy duration of 16 months.

  • 4

    Despite challenges, four children achieved long-term relapse-free survival, while six remained stable on maintenance antifungal therapy.

  • 5

    Talaromycosis may indicate underlying inborn errors of immunity in children, highlighting the need for prolonged antifungal and immunostimulatory therapy.

Original Source(s)

Related Content